Skip to main content
SpringerLink
Log in

MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers

  • Short Communication
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Colado MI, Williams JL, Green AR (1995) The hyperthermic and neurotoxic effects of ’Ecstasy’ (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 115:1281–1289

    PubMed  Google Scholar 

  2. de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Cami J (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26:137–144

    PubMed  Google Scholar 

  3. Farré M, de la Torre R, Ó Mathúna B, Roset PN, Peiró AM, Torrens M, Ortuño J, Pujadas M, Camí J (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173:364–375

    Google Scholar 

  4. Forsling ML, Fallon JK Shah D, Tilbrook GS, Cowan DA, Kicman AT, Hutt AJ (2002) The effect of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135:649–656

    PubMed  Google Scholar 

  5. Gouzoulis-Mayfrank E, Becker S, Pelz S, Tuchtenhagen F, Daumann J (2002) Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis? Biol Psychiatry 51:766–769

    PubMed  Google Scholar 

  6. Greene SL, Dargan PI, O’Connor N, Jones AL, Kerins M (2003) Multiple toxicity from 3,4-methylenedioxymethamphetamine (“ecstasy”). Am J Emerg Med 21:121–124

    PubMed  Google Scholar 

  7. Hatzidimitriou G, Tsai EH, McCann U, Ricaurte G (2002) Altered prolactin response to m-chlorophenylpiperazine in monkeys previously treated with 3,4-methylenedioxymethamphetamine (MDMA) or fenfluramine. Synapse 44:51–57

    PubMed  Google Scholar 

  8. Jones DC, Duvauchelle C, Ikegami A, Olsen CM, Lau SS, de la Torre R, Monks TJ (2005) Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J Pharmacol Exp Ther 313:422–431

    PubMed  Google Scholar 

  9. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136–145

    PubMed  Google Scholar 

  10. Pizarro N, Ortuno J, Farre M, Hernandez-Lopez C, Pujadas M, Llebaria A, Joglar J, Roset PN, Mas M, Segura J, Cami J, de la Torre R (2002) Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol 26:157–165

    PubMed  Google Scholar 

  11. Reist C, Mazzanati C, Vu R, Tran D, Goldman D (2001) Serotonin transporter promoter polymorphism is associated with attenuated prolactin response to fenfluramine. Am J Med Genet 105:363–368

    PubMed  Google Scholar 

  12. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284–295

    PubMed  Google Scholar 

  13. Schmid B, Bircher J, Preisig R, Kupfer A (1985) Polymorphic dextromethorphan metabolism: Co-segregation of oxidative o-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 38:618–624

    PubMed  Google Scholar 

  14. Segura M, Ortuno J, Farre M, McLure JA, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset PN, Segura J, de La Torre R (2001) 3,4-Dihydroxymethamphetamine (HHMA) A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 14:1203–1208

    PubMed  Google Scholar 

  15. Smith CAD, Gough AC, Leigh PN, Summers BA, Harding, AE, Maranganore DM, Sturman, SG, Schapira AHV, Williams AC, Spurr NK, Wolf CR (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson’s disease. Lancet 339:1375–1377

    PubMed  Google Scholar 

  16. Steen VM, Andreassen OA, Daly AK, Trefe T, Borresen AL, Idle JR, Gulbrandsen AK (1995) Detection of the poor metaboliser-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5:215–223

    PubMed  Google Scholar 

Download references

Acknowledgements

Supported in part by grants from Generalitat de Catalunya (2001SGR00407), Fondo de Investigacíon Sanitaria (98/0181 and 01/1336). We are indebted to research nurses Esther Menoyo and Isabel Sánchez for their valuable assistance throughout the clinical trial. We are also eternally grateful to the work and contribution made by our colleagues at the Section of Molecular Pharmacology and Pharmacogenetics, Division of Clinical Sciences (CSUHT), Sheffield, UK: S.W. Ellis and J. Chowdry for genotyping, and M.S. Lennard and G.T. Tucker for helpful advice.

Author information

Authors and Affiliations

  1. Pharmacology Unit, Institut Municipal d’Investigació Mèdica (IMIM), Doctor Aiguader 80, 08003, Barcelona, Spain

    Rafael de la Torre, Magí Farré, Brian Ó Mathúna, Pere N. Roset, Neus Pizarro, Mireia Segura, Jordi Ortuño, Mitona Pujadas & Jordi Camí

  2. Universitat Autònoma, Barcelona, Spain

    Magí Farré, Pere N. Roset & Marta Torrens

  3. Universitat Pompeu Fabra, Barcelona, Spain

    Rafael de la Torre, Brian Ó Mathúna & Jordi Camí

  4. IAPS-Hospital del Mar, Barcelona, Spain

    Marta Torrens

Authors
  1. Rafael de la Torre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Magí Farré
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brian Ó Mathúna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pere N. Roset
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Neus Pizarro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mireia Segura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marta Torrens
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jordi Ortuño
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mitona Pujadas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jordi Camí
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rafael de la Torre.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de la Torre, R., Farré, M., Ó Mathúna, B. et al. MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur J Clin Pharmacol 61, 551–554 (2005). https://doi.org/10.1007/s00228-005-0965-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0965-y

Keywords

Search

Navigation